Paul Campbell and Major League Baseball’s Joint Drug Prevention and Treatment Program / 2020s
Paul Campbell’s promising arrival in Major League Baseball was abruptly overshadowed by a failed drug test. Selected by the Miami Marlins from the Tampa Bay Rays in the December 2020 Rule 5 draft, the right-hander made the Marlins’ Opening Day roster and debuted in relief against Tampa Bay on April 3, 2021. He made his first MLB start on May 1, but only two days later MLB announced that he had been suspended for 80 games for violating the league’s Joint Drug Prevention and Treatment Program. The positive test involved dehydrochloromethyltestosterone, commonly known as DHCMT or Oral Turinabol, an anabolic-androgenic steroid associated with performance enhancement and historically linked to doping controversies in elite sport. The suspension came at a particularly damaging moment: Campbell had just reached the majors after several seasons of steady minor-league development, and the penalty immediately interrupted his first taste of MLB competition. He ultimately appeared in 16 games for Miami in 2021, posting a 6.41 ERA, and the doping case became the defining controversy of his brief major-league career. Later changes to the MLB-MLBPA drug program led some observers to describe DHCMT as having been removed from the banned-substance list, but anabolic steroids as a class remained prohibited; the later policy language did not erase Campbell’s 2021 violation or suspension.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.